Does a Pfizer-Allergan Deal Make Sense?

Umer Raffat, Evercore ISI research analyst, comments on Pfizer possibly being in advanced talks to buy Allergan for as much as $380 per share. He speaks with Bloomberg's Betty Liu on "Bloomberg Markets." (Source: Bloomberg)

Stockton, Wilson on Fundamentals Versus Technicals
55:43 - Katie Stockton, chief technical strategist at BTIG, and Mike Wilson, chief U.S. equity strategist at Morgan Stanley, discuss the outlook for markets and impact from President Trump. They speak with Bloomberg's Alix Steel and Jonathan Ferro on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Wilson Counters Growing Calls for Caution
  • Fanning Says Trump's Strategy Is More of the Same
  • Gallo Says Investors Are Looking for Next Piece of Sugar